At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Avastin (bevacizumab) +1 moredrug
Likely dose
Avastin (bevacizumab) 0.05 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Pre-operative Adjunctive Anti-VEGF on Growth Factors in Severe Proliferative Diabetic Retinopathy Requiring Surgical Management
In Brief
A clinical study evaluating Avastin (bevacizumab) and Sham injection for Retinal Detachment and Diabetic Retinopathy. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effect of anti-VEGF drug (Avastin) adminstration in eyes prior to surgical treatment for Traction retinal detachment (TRD) in patients with Proliferative Diabetic Retinopathy (PDR).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Detachment, Diabetic Retinopathy
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedJan 2011
Primary CompletionJul 2011
Study CompletionJul 2012
TodayJul 2026
First PostedJan 5, 2011
Enrollment StartJun 1, 2009
Primary CompletionJul 1, 2011
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.5 years ago
Interventions
Avastin (bevacizumab)drug
single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
Sham injectionother
Subject's eyes will be anesthetized but no injection will be performed.